Background Cilostazol and ticlopidine are commonly prescribed for prevention of thrombosis after coronary stenting, but few studies have compared them.
tent implantation reduced the rates of acute occlusion and restenosis after percutaneous coronary intervention (PCI), 1 but a new type of problem emerged, namely, subacute thrombosis (SAT) within the stent and it is again highlighted in the present drug-eluting-stent era. Colombo et al reported that after stent implantation, anticoagulants can be replaced by a combination of antiplatelet therapy with ticlopidine and aspirin. 2, 3 However, serious adverse drug reactions (ADR), including hepatic dysfunction, granulocytopenia, interstitial pneumonia and thrombotic thrombocytopenic purpura (TTP), have been reported with ticlopidine. [4] [5] [6] Cilostazol, similar to ticlopidine, is used to prevent SAT after stent implantation and is also expected to reduce the incidence of restenosis, 7, 8 with milder adverse effects than ticlopidine. Yoon et al reported that antiplatelet therapy with cilostazol + aspirin was as effective as ticlopidine + aspirin in preventing stent thrombosis and there was no statistical difference in the incidence of ADR and complications. 9 However, those patients had undergone elective coronary stenting, so it remains unclear whether antiplatelet therapy with cilostazol + aspirin is equally effective as ticlopidine + aspirin in emergency PCI cases in the "real world".
We therefore designed the present study to evaluate and compare the clinical effects of cilostazol vs ticlopidine after stent implantation with respect to SAT rate, restenosis rate, cardiac events, and ADR in consecutive patients undergoing emergency PCI, including acute coronary syndrome (ACS).
Methods

Patients Selection and Drug Regimens
Between August 1997 and January 2002, 642 consecutive patients with ischemic heart disease who underwent revascularization by implantation of coronary stent were randomized to treatment with cilostazol 200 mg/day + aspirin (C group, 321 patients) or ticlopidine 200 mg/day + aspirin (T group, 321 patients). The randomization was performed with a standard list of random numbers. The administration of the antiplatelet agents was open label (ie, the physicians and patients were not blinded). Treatment was continued for at least 6 months after stent implantation until follow-up angiography was performed. Oral aspirin was started at a dose of 81-200 mg/day prior to the procedure, and oral cilostazol or ticlopidine was started 2 h after stent implantation. Heparin was administered during the PCI, but was continued for 2 or 3 days after the procedure only in patients with acute myocardial infarction. Warfarin was not prescribed. A variety of stents were used for implantation at the lesion site, with selection left to the discretion of the treating physician. Exclusion criteria included active hepatitis or liver cirrhosis, active internal bleeding, or an absolute contraindication to anticoagulation. The study protocol was approved by the Institutional Review Board of Tsukuba Medical Center Hospital and written informed consent was obtained from all subjects before randomization.
Definitions
Restenosis was defined as >50% diameter stenosis at the intervention site on follow-up angiography. The diagnosis of distal embolism was based on angiographic cut-off of a distal branch or vessel at any point during the procedure and/or decreased flow in a distal vessel that was previously patent in the absence of an occlusion at the site of the target lesion. SAT was defined as angiographic documentation of stent occlusion within 30 days of the procedure compared with after 24 h, and acute thrombosis was defined as stent occlusion within 24 h. The occurrence of ADR including rash, purpura, diarrhea, nausea, gastrointestinal bleeding, cytopenia, hepatic dysfunction and renal dysfunction were prospectively monitored. Neutropenia was defined as neutrophil count <1,200 /mm 3 and thrombocytopenia as a reduction in the platelet count to <80,000 /mm 3 or a relative reduction of the platelet count to <50% of baseline. Hepatic dysfunction was defined as an increase of aspartate transaminase or alanine transaminase more than 2-fold the upper limit of normal and renal dysfunction as an increase of serum creatinine >0.5 mg/dl above baseline. Hematologic status was evaluated every 2 or 4 weeks after the first administration of the drug. If patients had any side effects, the study drug was discontinued.
Angiographic Analysis and Follow-up
Quantitative coronary angiography was performed (QCA; Quantocor, Siemens, Erlangen, Germany) at baseline (before and immediately after procedure) and at 6-month follow-up to measure the reference diameter and minimal lumen diameter (MLD) of the lesion site, percent stenosis, and lesion length. In addition, the restenosis rates, target lesion revascularization (TLR) rates, acute thrombosis and SAT rates, and incidence of ADR were compared between the 2 treatment groups.
Follow-up endpoints included restenosis, acute thrombosis or SAT, reintervention at the stent placement site, and serious ADR.
Statistical Analysis
All values are expressed as the mean ± standard deviation. Repeated-measure ANOVA was used for statistical analysis to compare the QCA values. The Mann-Whitney U test or chi-square test was used to analyze comparisons of baseline clinical and angiographic characteristics. A pvalue less than 0.05 was considered statistically significant.
Results
Baseline Characteristics
There were 436 target lesions in the T group and 428 target lesions in the C group. Baseline characteristics including age, gender, coronary risk factors did not significantly differ between the 2 groups (Table 1) , nor were there significant differences in a history of myocardial infarction or coronary artery bypass surgery. The number of patients diagnosed as ACS at the time of procedure was not significantly different between the groups.
Angiographic Characteristics, Stent Type and Stent Implantation Procedure Characteristics
With the exception of a higher rate of stent implantation in a venous graft in the C group (4 patients) compared with the T group (0 patients), there were no other significant differences in the angiographic characteristics between the 2 groups ( Table 2 ). The lesion types at the stent placement site did not significantly differ, nor was there a significant difference in the type of the stent implanted or the stent implantation procedure characteristics (Fig 1, Table 3 ).
QCA Data
QCA analysis at the time of stent implantation showed no significant differences in reference diameter, MLD before or immediately after the procedure, or lesion length (Table 4) . On 6-month follow-up QCA, the MLD at the stent implantation site did not significantly differ between the T group (2.00±0.65 mm) and the C group (2.04± 0.64 mm) (Fig 2) . There were also no significant differences in restenosis rate (T group, 29.3%; C group, 27.8%) or TLR rate (T group, 23.5%; C group, 22.4%).
Clinical and Angiographic Events
Angiographic events within the 6 months included a significantly higher rate of distal embolism during the procedure in the C group (10 patients, 3%) compared with the T group (3 patients, 1%), and a significantly higher rate of stent SAT in the C group (8 patients, 2% vs 1 patient, 0.3% in T group) ( Table 5, Fig 3) . Acute stent thrombosis did not occur in either group. Clinical events within 1 month included a significantly higher rate of repeat intervention (revascularization) in the C group (9 patients, 3%) compared with the T group (1 patient, 0.3%); however, there were no significant differences in the rates of emergency coronary artery bypass grafting, myocardial infarction, or death (Table 5 ). In a comparison of patient characteristics, angiographic characteristics and procedural characteristics between patients with SAT (n=9) and those without SAT (n=633), the only significant difference was the drug regimen (p=0.0188).
ADR
The incidence of ADR did not significantly differ between the T group (22 patients, 7%) and C group (12 patients, 4%), although there was a significantly higher incidence of "purpura" in the T group (4 patients, 1% vs 0 patients, 0% in the C group). No life-threatening ADR, such as TTP or severe hepatic dysfunction, occurred in either group (Table 6) .
Discussion
This prospective randomized study found no significant difference in stent restenosis, TLR or composite frequency of ADR between the use of cilostazol + aspirin or ticlopidine + aspirin. However, the incidence of stent thrombosis during the 6 months after coronary stenting was significantly higher with cilostazol than with ticlopidine.
It is considered that cilostazol will reduce the incidence of cardiac events and restenosis after coronary artery intervention by virtue of its antiplatelet effects and inhibition of vascular smooth muscle cell proliferation. The drug's effects on prevention of restenosis after plain old balloon angioplasty without a stent have been reported, 10 and the primary mechanism of action is considered to be inhibition of intimal hyperplasia. [11] [12] [13] Cilostazol has also been reported to prevent restenosis after stent implantation by Kozuma et al 13 who thought it might be more beneficial in preventing both angiographic and clinical restenosis after stenting than ticlipidine. However, this is still controversial.
In our study, which included patients with ACS, there was no significant difference between cilostazol and ticlopidine in preventing restenosis after stent implantation. Similarly, in a randomized trial of "cilostazol + aspirin" vs "ticlopidine + aspirin" in 409 patients who underwent elective stenting, Park et al also reported no significant differences in restenosis rate. 14 The antiplatelet effects of cilostazol are pharmacologically potent, in addition to those of aspirin and ticlopi- dine, 15, 16 but the time to onset of the inhibitory effect on platelet aggregation in vivo of cilostazol is shorter than that of ticlopidine. 17 "Ticlopidine + aspirin" became established as a post-stent treatment regimen after reports by Colombo et al, 2, 3 but ticlopidine is associated with potentially lifethreatening ADR, including severe hepatic dysfunction, granulocytopenia, interstitial pneumonia and TTP. 4, 5 Thus, the alternative regimen of "cilostazol + aspirin" has been proposed because of its potentially less severe ADR. Several previous studies have demonstrated that the new combination is a safe and effective post-stenting antithrombotic regimen that is comparable to the standard ticlopidine + aspirin regimen; 13, 18, 19 However, in the present study, the rate of SAT was significantly higher in patients given the cilostazol combination. In other words, it was inadequate as a post-stenting treatment regimen. In a recent study, Sekiguchi et al reported that ticlopidine + aspirin showed less SAT after stenting compared with cilostazol + aspirin 20 and Isshiki also reported that in a meta-analysis study the incidence of SAT after coronary stenting was 0.8% in patients with the ticlopidine + aspirin regimen and 4.0% in patients given cilostazol + aspirin. 21 The results of our study are consistent with these studies. Cilostazol is as pharmacologically potent as ticlopidine in its inhibition of platelet functions, 15, 16 but the mechanism of the 2 agents is different. The ADP receptor has a significant role during arterial thrombus formation [22] [23] [24] and ticlopidine directly inhibits the ADP receptor on platelet cells. 25 In contrast, cilostazol inhibits ADP-induced platelet aggregation by indirectly inhibiting cyclic-AMP phosphodiesterase. This different antiplatelet mechanism might be the reason for the greater effect of ticlopidine on the incidence of SAT after stenting.
The incidence of distal embolism after stenting was significantly higher in the C group than in the T group, but the occurrence of SAT was not related to the occurrence of distal embolism. Using a protective device during stenting will prevent distal embolism. 26, 27 Although not significantly different, the incidence of ADR in our study was slightly higher with ticlopidine, but none was serious. Because a patient on ticlopidine developed TTP prior to this study, all patients on antiplatelet therapy are monitored by laboratory studies every 2 weeks to minimize the possible development of ADR. The possibility of TTP in patients taking ticlopidine is now widely recognized, which may be contributing to the lower incidence of serious ADR with this antithrombotic regimen.
Study Limitations
This study was a prospective randomized but not double-blind trial, enrolled in a single center with a moderate number of patients. A large, double-blind, multicenter trial is required to confirm our results. We did not use intravascular ultrasound, which would have enable us to obtain more quantitative information, including neointimal formation.
Conclusion
This randomized comparison of "cilostazol + aspirin" vs "ticlopidine + aspirin" as antiplatelet therapy after coronary stent implantation showed a similar rate of restenosis for both regimens. However, the rate of SAT was significantly higher with "cilostazol + aspirin". There were no significant differences in the incidence of ADR.
